Pharma channel feed

Mega-block­buster? Pfiz­er lines up for a snap re­view of its PARP drug ta­la­zoparib — and a launch in­to a crowd­ed mar­ket

7 years ago

Genen­tech dives deep­er in­to the mi­cro­bio­me, ink­ing $534M deal with Mi­cro­bi­ot­i­ca to de­vel­op IBD meds

7 years ago

Pick­ing up the pieces left from an Alzheimer’s im­plo­sion, Ax­o­vant is start­ing over by div­ing in­to gene ther­a­py

7 years ago
R&D

Gilead ups its bet on HIV, hep B, ink­ing $400M part­ner­ship with im­munother­a­py com­pa­ny Hookipa

7 years ago
R&D

With com­pe­ti­tion on its heels, Blue­print takes three can­cer drugs to Chi­na

7 years ago
China

Spurring move to per­son­al­ized ther­a­pies, Loxo el­bows its way back in­to the AS­CO spot­light with 2nd tis­sue-ag­nos­tic can­cer drug suc­cess

7 years ago
R&D

FDA stalls yet an­oth­er Her­ceptin copy­cat, is­su­ing re­sponse let­ter to Am­gen/Al­ler­gan

7 years ago

FDA quash­es block­buster dreams at Eli Lil­ly and In­cyte, of­fer­ing a se­vere­ly lim­it­ed ap­proval for Olu­mi­ant

7 years ago

The FDA and the EMA go their sep­a­rate ways on DMD: CHMP slaps down Sarep­ta but of­fers ri­val PTC an ex­pand­ed mar­ket

7 years ago

Di­min­ish­ing the FDA’s pow­er was my in­tent: Right-to-try au­thor scolds Scott Got­tlieb as agency im­ple­ments new law

7 years ago

Bay­er scru­ti­nizes R&D group's pro­duc­tiv­i­ty as staffers fear lay­offs in wake of a re­vamp

7 years ago
R&D

Do­va picked up its new­ly ap­proved drug castoff for a song — but pay­ers will be singing the blues about the price

7 years ago

Fol­low­ing AS­CO pre­view flop, Syn­dax bets on new com­bo deal with Nek­tar

7 years ago
R&D

Af­ter track­ing suc­cess in an­i­mals, neu­ro­sciences star De­nali moves ear­ly to bag an op­tion on a promis­ing tech for cross­ing the blood-brain bar­ri­er

7 years ago

Trump signs right-to-try bill, says 'mas­sive' vol­un­tary drug price cuts com­ing in two weeks

7 years ago

J&J hus­tles Leg­end’s promis­ing BC­MA CAR-T in­to PhI/II tri­al, win­ning an FDA green light to be­gin re­cruit­ing pa­tients

7 years ago
R&D

FDA moves Sage’s post­par­tum de­pres­sion drug brex­anolone in­to reg­u­la­tors’ busy pri­or­i­ty lane

7 years ago
R&D

FDA ex­e­cutes a 180 on Ther­a­peu­tic­sMD ther­a­py, hand­ing it an OK — and stok­ing con­cerns about po­lit­i­cal in­flu­ence

7 years ago

AS­CO loom­ing, Loxo, Bay­er line up a quick shot at FDA OK for their ground­break­ing ap­proach to can­cer ther­a­py

7 years ago

Those open of­fices bio­phar­ma ex­ecs love so much? Most staffers hate them with a pas­sion

7 years ago

Bio­Marin gets its shot at an­oth­er block­buster as FDA OKs rare dis­ease drug peg­valiase

7 years ago

Astel­las shed­ding 600-plus jobs as CEO shakes up R&D and sales ops in re­struc­tur­ing

7 years ago
R&D

Cara hauls in $70M on first leg of glob­al deal, set­ting up PhI­II kid­ney dis­ease drug for com­mer­cial roll out

7 years ago
R&D

House pass­es 'right-to-try' — al­low­ing the ter­mi­nal­ly ill to ask com­pa­nies for ex­per­i­men­tal drugs out­side of FDA's purview

7 years ago
First page Previous page 296297298299300301302 Next page Last page
A service from the Financial Times